Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis

Brucellosis is a disease of domestic and wild animals that is transmitted to humans and exists worldwide. We assessed the in vitro activity of moxifloxacin, ciprofloxacin, tetracycline, doxicycline, rifampin, streptomycin and trimethoprim-sulfamethoxazole (TMP/SMX) against 97 Brucella strains isolated from clinical samples, animals and dairy products in Mexico. Fluoroquinolones showed an antibacterial activity similar to that of tetracyclines (MIC(90) 0.5). Other drugs commonly used against brucellosis were less active, such as rifampin (MIC(90) 2.0 microg/ml) and streptomycin (MIC(90) 4.0 microg/ml). TMP/SMX showed the poorest activity (MIC(90) 8.0 microg/ml). Fluoroquinolones, either first-generation or the newer 8-methoxi derivatives, might be useful in the therapy of brucellosis, which remains to be assessed in clinical trials.     

内蒙古乌兰察布地区布鲁氏菌体外药物敏感性及耐药机制分析

目的 调查内蒙古乌兰察布地区分离布鲁氏菌的抗生素药物敏感(耐受)性特征。方法 采用E-test法测定了85株布鲁氏菌对13种临床常用药物的敏感性;同时,对利福平和阿奇霉素的耐药机制进行了初步探讨;并采用K-B法对来自全国的149株羊种布鲁氏菌对复方新诺明和利福平的敏感性进行了筛查。结果 试验表明布鲁氏菌对阿奇霉素、复方新诺明和利福平耐药菌株数分别为100%(85/85),7.0% (6/85)和 1.0% (1/85)。所有菌株对司帕沙星、米诺环素、多西环素、四环素、链霉素、庆大霉素、左氧氟沙星、环丙沙星、头孢吡肟及头孢哌酮舒巴坦均表现为敏感;司帕沙星、米诺环素的MIC₉₀值(0.032 μg/mL)最低。所有阿奇霉素耐药菌株的23S rRNA基因的第2632位碱基表现为T→C单位点突变,布鲁氏菌23S rRNA转肽酶中心的T/C点突变可能是一种羊种布鲁氏菌对阿奇霉素耐药的分子机制。K-B法筛查结果表明所有菌株对利福平敏感,25.5%(38/149)的菌株对复方新诺明耐药,耐药菌株分布于18个省市区。结论 乌兰察布地区羊种布鲁氏菌耐药较为严重,应定期进行药物敏感性监测。推荐司帕沙星和米诺环素作为一线布病治疗药物。     

内蒙古乌兰察布布氏菌分离株种型鉴定及流行病学特征分析

目的 鉴定临床分离布氏菌种型,并分析患者的流行病学特征。方法 以牛种、羊种、猪种标准参考菌株为试验对照,采用经典方法和VITEK2.0进行初步鉴定,用AMOS-PCR进行确证,并分析患者的流行病学特征。结果 经典鉴定115株均为羊种菌,羊3型93株,羊1型22株;115株菌ProA、TyrA、URE和GlyA全部阳性;91株ELLM阳性、14株APPA阳性,提示均为布氏菌,其中羊种菌91株,猪种菌14株。与经典实验的鉴定符合率比较鉴定布氏菌属100%,鉴定布氏菌种为79%(91/115);AMOS-PCR均获得了约731 bp的特异性扩增条带,证实全部为羊种菌。初诊患者84例,构成比为73%;临床表现以疼痛、发热、乏力、多汗居多;88例患者就诊前无用药史,2例有布病治疗史。结论 VITEK2.0是一种高效的布氏菌鉴定方法,但不能替代经典方法;羊种3型菌为该地区的主要流行菌种,再感染可能是慢性患者或有布病治疗史患者分离到布氏菌的主要因素,初诊、未用抗生素且症状典型是分离布氏菌的重要指标。     

左氧氟沙星体外诱导马耳他布鲁杆菌耐药后gyrA基因的变异

目的 探讨马耳他布鲁杆菌对喹诺酮类抗菌药物耐药性的产生机制,为指导临床合理用药提供依据.方法 使用左氧氟沙星分别对6株马耳他布鲁杆菌(Bru1、Bru2、Bru3、Bru4、Bru5、Bru6)进行体外耐药诱导并筛选耐药菌株.采用琼脂稀释法测定左氧氟沙星对6株马耳他布鲁杆菌及诱导耐药菌株的最低抑菌浓度(MIC),采用纸片扩散法(K-B法)测定6株马耳他布鲁杆菌和诱导耐药菌株对喹诺酮类抗菌药物(左氧氟沙星、环丙沙星、洛美沙星、诺氟沙星、氟罗沙星、氧氟沙星)的敏感性.应用PCR技术扩增6株马耳他布鲁杆菌及诱导耐药菌株的gyrA基因,并对获得的基因进行同源性分析及氨基酸序列推导.结果 左氧氟沙星对Bru1,Bru2,Bru3,Bru4,Bru6菌株MIC为0.50 μg/ml,对Bru5菌株为0.25 μg/ml,菌株Bru3、Bru4经左氧氟沙星诱导后转变成耐药菌株,分别命名为LEVR3及LEVR4,其MIC分别为64.00、128.00 μg/ml,与诱导前比较,增加了128倍和256倍,6株马耳他布鲁杆菌对上述喹诺酮类药物均敏感,2株诱导耐药菌株对上述喹诺酮类药物均耐药,并且其GyrA亚单位的喹诺酮耐药性决定区(Quinolone resistance-determing region,QRDR)发生突变:Ala87(GCU)置换为Val(GUU)、Asp91(GAU)置换为Gly(GGU).结论 马耳他布鲁杆菌可在左氧氟沙星短期作用后获得耐药性,诱导的耐药菌株gyrA基因发生突变,且对其他喹诺酮类药物产生交叉耐药.     

Antibiotic susceptibility of Neisseria meningitidis from healthy and diseased persons in Japan

We examined the susceptibilities of 100 Neisseria meningitidis strains isolated between 1990 and 2004 to 12 antimicrobial agents, finding the MIC50 to be 0.031 microg/mL and that of MIC90 of benzylpenicillin (PCG), a type of penicillin, to be 0.063 microg/mL. Two strains showed intermediate resistance (MIC of 0.125-0.25 microg/mL). Two strains of the same origin also showed intermediate resistance (0.25-1 microg/mL) to ampicillin (ABPC). For cephems, MIC50 and MIC90 of cefotaxime (CTX) were both 0.004 microg/mL, while the MICs of ceftriaxone (CTRX) were all 0.004 microg/mL, showing the strongest antibacterial spectrum. The three carbapenems surveyed meropenem (MEPM), panipenem (PAPM), and imipenem (IPM) also had a strong antibacterial spectrum in ascending order, with the MIC50 and MIC90 of MEPM, which was lowest, being 0.008 microg/mL and 0.016 microg/mL. Some 97% of MICs for ciprofloxacin (CPFX) were 0.004 microg/mL but 3 strains showed resistance (0.125 microg/mL). No difference was seen between MICs of N. meningitidis strains originated from meningitis patients, patients other than meningitis, and healthy carriers. No difference was seen in MICs by serogroup (A, B, C, Y, W135 and NG).     

2009-2012年宁夏人群感染布鲁氏菌种型分布特征

目的鉴定2009—2012年宁夏分离的布鲁氏菌,掌握感染人群的主要布鲁氏菌种型。方法采用血培养瓶从试管凝集试验（SAT）抗体阳性的病人血液中分离布鲁氏菌,利用传统生物学特性鉴定方法结合聚合酶链式反应（PCR）和A,M,O,S-聚合酶链式反应（AMOS-PCR）方法进行种型鉴定。结果从目标人群中共分离22株菌,PCR检测均扩增出223bp的特异性条带,鉴定为布鲁氏菌。AMOS-PCR中均扩增出178bp和731bp的特异性条带,鉴定为羊种布鲁氏菌,结合染料抑菌试验、噬菌体裂解和特异性血清凝集试验结果,22株菌均为羊种3型布鲁氏菌。结论2009—2012年宁夏人群感染布鲁氏菌主要为羊种3型布鲁氏菌,PCR和AMOS-PCR可作为布鲁氏菌分离鉴定的辅助方法推广使用。     

福建省布鲁氏菌分离株的分子生物学鉴定

目的利用分子生物学方法鉴定福建省布鲁氏菌分离株。方法对布鲁氏菌分离株进行AMOS-PCR和MLVA分型。结果3株福建省分离株经AMOS-PCR鉴定为羊种,与传统生物学分型一致;MLVA分型将其分为3个基因型,聚类分析鉴定为羊种。结论AMOS-PCR、MLVA分型可以作为我省布鲁氏菌分离株鉴定的辅助手段。     

贵州省两株山羊源羊种布鲁菌MLST分析

目的了解贵州省2010年分离自山羊的两株羊种布鲁菌的等位基因序列型(Sequence type, ST)及遗传学特征,为动物间和人间布病疫情的预防和控制提供科学依据。方法应用布鲁菌属特异性PCR(BCSP31-PCR)和种/型特异性PCR(AMOS-PCR)对2010年分离自山羊的两株布鲁菌进行鉴定,采用多位点序列分型(Multiple locus sequence typing, MLST)技术对两株布鲁菌菌株的7个管家基因、1个外膜蛋白基因及1个基因间区的序列进行测定,将各个基因的序列与参考菌株的等位基因型进行比对,确定其等位基因谱及序列型(STs),分析与两株菌ST型与各种型布鲁菌代表菌株的遗传进化关系。结果来自贵州省山羊的两株布鲁菌株经BCSP31-PCR鉴定为布鲁菌属细菌,AMOS-PCR将其鉴定为羊种布鲁菌。MLST分析显示,两株菌的9个等位基因序列型为ST8型,与同属羊种布鲁菌的ST7、ST9~ST12、ST34和ST35遗传关系最近。结论贵州省2010年分离的2株布鲁菌分离株均为ST8型布鲁菌,与同属羊种布鲁菌的ST型遗传关系最近,结果为贵州省人间和动物间布病疫情的预防和控制提供了科学依据。     

Prevalence of vancomycin and high level aminoglycoside resistant enterococci among high-risk patients

Enterococci have been recognized as clinically important pathogens in high-risk populations of hospitalized patients. The role of enterococci in nosocomial infections is being recognized with increasing frequency. The main source of these infections is usually fecal carriage of the microorganisms. In this study, gastrointestinal colonization with vancomycin resistant enterococci (VRE) and high-level aminoglycoside resistant enterococci among 316 high-risk hospitalized patients were investigated. One hundred and ninety-eight enterococci strains were isolated from stool specimens. All strains were identified to species level and 90 of the isolates were identified as Enterococcus faecalis (45%), 85 as E. faecium (21.5%), 14 as E. avium (7%), 7 as E. raffinosus (3.5%), 1 as E. durans (0.5%) and 1 as E. hirae (0.5%). Eleven of 198 strains were found to be moderately sensitive to vancomycin (MIC: 8-16 microg/ml) by the agar dilution method according to the National Committee for Clinical Laboratory Standards (NCCLS) recommendations, and the rest of these strains were found to be sensitive (MIC < or = 4 microg/ml). Twenty-eight strains showed high-level resistance to streptomycin (2,000 microg/ml) and 26 strains were found to have high-level resistance to gentamicin (500 microg/ml). Twelve of these strains had high-level resistance to both aminoglycosides. By the disk diffusion tests, 53 of 198 strains were found to be resistant to erythromycin, 51 to penicillin, 37 to ampicillin, 18 to ciprofloxacin, 14 to norfloxacin and 3 to nitrofurantoin. No beta-lactamase production was detected in 198 studied strains.     

Molecular epidemiology of Haemophilus influenzae strains isolated from patients with meningitis during 1999 to 2003

A total of 535 Haemophilus influenzae strains from 226 Japanese institutions participating in the Nationwide Surveillance Study Group for Bacterial Meningitis were sent to our laboratory during 1999 to 2003. All strains were analyzed by PCR to identify the beta-lactam resistance genes, and their susceptibilities to beta-lactam agents were determined. These strains were classified into 6 genotype patterns and MIC90 values for ampicillin (ABPC): (i) beta-lactamase nonproducing, ABPC susceptible (BLNAS) strains and lacked all resistance genes (27.7% of isolates; MIC90, 0.5 microg/ml); (ii) beta-lactamase producing, ABPC resistant (BLPAR) strains (12.9%, 16 microg/ml); (iii) beta-lactamase nonproducing, ABPC resistant (Low-BLNAR) strains with a Asn526Lys amino acid substitution in ftsI gene encoding PBP3 (31.2%, 2 microg/ml); (iv) beta-lactamase nonproducing, ABPC resistant (BLNAR) strains with Ser385Thr and Asn526Lys substitutions in ftsI (17.2%, 8 microg/ml); (v) amoxicillin/clavlanic acid resistant (BLPACR I) strains, having beta-lactamase gene and a Asn526Lys amino acid substitution in ftsI (9.2%, 32 microg/ml); and (vi) amoxicillin/clavlanic acid resistant (BLPACR II), having beta-lactamase gene and ftsI substitutions as for BLNAR strains (1.9%, 64 microg/ml). All but 4 strains were serotype b. The prevalence of BLNAR strains has increased exponentially: 0% (n = 0/41) in 1999, 5.8% (n = 4/69) in 2000, 14.1% (n = 19/139) in 2001, 20.1% (n = 32/159) in 2002, and 29.1% (n = 37/127) in 2003. The MIC90s of BLNAR isolates except for ABPC were as follows: piperacillin, 0.125 microg/ml; ceftriaxone, 0.25 microg/ml; meropenem, 0.5 microg/ml; cefotaxime, 1 microg/ml; panipenem, 2 microg/ml; cefozopran, 16 microg/ml; and cefotiam, 64 microg/ml. To prevent such resistance from increasing, expedited vaccination, correct identification of the BLNAR molecularly, and the proper selection of proper antibiotics based on PK/PD must be taken.     

贵州省首次从山羊分离到布鲁氏菌及其种型鉴定

目的从贵州布鲁氏菌抗体阳性的山羊血液分离布鲁氏菌病原体并对其进行种型鉴定。方法采用血培养法对经试管凝集试验检测为布鲁氏菌抗体阳性的山羊血血液进行细菌分离培养,并应用传统方法和和分子生物学方法对可疑菌落进行种型鉴定。结果11份（GZB 01—11）抗体阳性的山羊血标本中有4份（GZB03、GZB04、GZB09、GZB11）经血培养瓶培养出布鲁氏菌可疑菌落,可疑菌落经传统方法鉴定为羊种生物3型布鲁氏菌,4株菌进一步采用布鲁氏菌属特异性PCR（BCSP31-PCR）鉴定为布鲁氏菌属细菌,GZB03,GZB04,GZB11经种／型特异性PCR（AMOS-PCR）将其定为羊种布鲁氏菌,而GZB09采用该方法不能定种。结论从11份贵州省布鲁氏菌抗体阳性山羊血样中分离到4株羊种布鲁氏菌,首次证实贵州省存在羊种布鲁氏菌。     

Phagocytosis and killing of Brucella by human polymorphonuclear leukocytes

Although cellular immunity involving activated macrophages is important in resistance to Brucella, serum factors and polymorphonuclear leukocytes (PMNLs) play some role in the initial response to infection. The interaction between human PMNLs and virulent and attenuated strains of Brucella abortus and Brucella melitensis was studied by in vitro techniques. Virulent and attenuated strains of both species were rapidly phagocytosed after opsonization with normal human serum (NHS); nonopsonized bacteria were not phagocytosed. In contrast, NHS devoid of detectable antibodies was bactericidal for strains of B. abortus but not of B. melitensis. In addition, intracellular killing of ingested bacteria was shown for virulent B. abortus but not for B. melitensis. Ultrastructural studies revealed morphological alterations in about one-half of phagocytosed B. abortus and B. melitensis after incubation for 10 min; thereafter, nearly 100% of B. abortus showed some degree of degeneration, whereas B. melitensis remained intact during 120 min of observation.     

牛羊猪种布鲁氏菌快速鉴别PCR方法的建立及评价

目的 建立一种可在一个反应体系中同时鉴别布鲁氏菌及牛羊猪种布鲁氏菌的快速PCR鉴别方法。方法 将布鲁氏菌及牛羊猪种布鲁氏菌的扩增引物进行优化组合,建立全新的BAMS-PCR方法;随后对该方法的特异性和灵敏度进行评价,并对现场分离的219株布鲁氏菌进行鉴别,评价其在布鲁氏菌鉴别中的应用价值。最后,用该方法对临床标本中布鲁氏菌的DNA进行扩增,评价其在临床诊断中的实用性。结果 BAMS-PCR方法可在同一反应中同时鉴别布鲁氏菌及牛种(1,2,4型),羊种(1,2和3型)和猪种(1型)布鲁氏菌,并有较好的特异性和敏感性。布鲁氏菌属,牛种,猪种和羊种布鲁氏菌引物的检测灵敏度分别为10 pg/μL,100 pg/μL, 10 pg/μL和100 pg/μL。BAMS-PCR对219株临床分离菌株的鉴定结果和常规生物分型方法的鉴定符合率为100%。经BAMS-PCR检测,97份临床血清样本仅6份为阳性,全血和组织(羊脾)样本全部为阴性。结论 BAMS-PCR是一种简便、快速、高效、准确的布鲁氏菌鉴别方法,可作为临床分离菌株的首选鉴别方法。     

2018年江苏省人感染布鲁氏菌分离株分子特征分析

目的 掌握江苏省2018年人感染布鲁氏菌主要流行株的种型和基因型。方法 运用普通PCR及AMOS多重PCR确认分离株的生物种型;采用多位点序列分型(Multilocus sequence analysis, MLSA)和多位点串联重复序列分析(Multiple-locus variable number tandem repeat analysis, MLVA)鉴定基因型,并与国内外流行株进行聚类分析。结果 2018年共分离到56株布鲁氏菌,MLSA分型显示一株菌为猪种布鲁氏菌ST (Sequence type)17型,其他均为羊种布鲁氏菌ST8型。MLVA将56株菌分为47个基因亚型(46个羊种,1个猪种),聚类显示羊种布鲁氏菌全部为“东地中海簇”。结论 2018年江苏省人感染布病主要为“东地中海簇”的ST8型羊种布鲁氏菌,并首次发现一例人感染ST17型猪种布鲁氏菌。     

内蒙古布鲁氏菌临床分离株多位点序列分型研究

目的探讨临床分离布鲁氏菌的种群结构和遗传进化特征。方法布鲁氏菌标准参考菌株羊种16M,牛种544A和猪种1 330 S作为对照菌株,采用多位点序列分型(Multiple locus sequence typing,MLST)方法对内蒙古地区分离的116株羊种布鲁氏菌进行分析,确定待测菌株的序列型(STs),用软件BioNumerics(Version 5.0)构建菌株的最小生成树。结果116株羊种布鲁氏菌全部为ST8型,9个MLST位点的变异完全相同,分离株种群结构单一;羊种菌的生物型与ST型无明显关联,ST8型菌系该地区的主要流行菌种,并与内蒙古地区先前分离羊种布鲁氏菌进化程度相同,且有密切的亲缘关系。结论羊种布鲁氏菌的序列分型(ST)与常规生物分型存在差异,ST8型菌可能具有较强的环境适应性和致病性。MLST是一种较好的羊布鲁氏菌种群和进化关系研究方法,但更适合于具有较大时间跨度和地理分布菌株间的流行病学调查。     

内蒙古羊种布鲁氏菌传播模式调查研究

目的 调查内蒙古羊种布鲁氏菌的传播模式和流行规律。方法 采用AMOS-PCR对60株布鲁氏菌的种型进行鉴定,用Hunter-Gaston Diversity Index(HGDI)评价菌株的遗传多态性特征,采用MLVA-16分型方法对菌株进行基因分型,确定菌株的亲缘关系。结果 60株试验菌全部为羊种布鲁氏菌。MLVA-16对菌株具有极高的分辨力,多态性指数为0.981;Panel 1,Panel 2A和Panel 2B的多态性指数分别为0.264,0.345和0.980;Panel 2B中Bru16位点的多态性指数最高,多态性指数为0.835。60株羊种布鲁氏菌聚为5大类37个基因型,其中15个共享基因型包括38株羊种布鲁氏菌,聚类率为63.3%(38/60),提示病例多为有流行病学关联的暴发流行;另外22株菌表现为独特基因型表明菌株无明显的流行病学相关性。共享基因型GT5包括2株分别分离自羊和骆驼的菌株且有相同的MLVA-16基因型,提示布鲁氏菌在羊和骆驼中循环传播;3个共享基因型(GT11、GT17和GT23)分别包含来自人和羊的菌株并呈现完全相同的MLVA-16基因型,表明羊是人间布病的传染源。GT35由3株分离自羊脾的菌株构成且共享相同的基因型,提示布病在羊中呈暴发流行。类群E由12个来自不同宿主(羊,牛,野生骆驼和人)的菌株构成,共享相同或相似的MLVA-16基因型,揭示了内蒙古羊种布鲁氏菌潜在的传播模式。结论 疫羊是主要传染源,野生动物(骆驼)是贮藏宿主。羊种布鲁氏菌在羊牛(骆驼)和骆驼(羊牛)中相互循环传播,最后传染给人是内蒙古羊种布鲁氏菌的潜在传播模式。     

石榴皮对幽门螺杆菌的体外抑菌实验研究

目的 探讨石榴皮对幽门螺杆菌（H．pylori）甲硝唑耐药株及敏感株的体外抑制作用。方法 琼脂稀释法检测石榴皮水煎剂对H．pylori甲硝唑耐药株和敏感株的最低抑菌浓度（MIC），并计算MIC50、MIC75、MIC90。结果 石榴皮对H．pylori的MIC的范围为7．8125-500mg／ml，H．pylori甲硝唑耐药株和敏感株对石榴皮水煎剂的敏感性无统计学差异（相对中位数潜力1．072，95％的可信区间为0．763-1.513），石榴皮对H．pylori甲硝唑耐药株和敏感株的MIC50分别为29．9mg／ml和28．0mg／ml，MIC75分别为65．1mg,／ml和59．1mg/ml，MIC90分别为131．1mg／ml和115．9mg／ml。结论 石榴皮有良好的抑菌效果，H．pylori甲硝唑耐药株及敏感株都对其敏感。     

陕西省布鲁氏菌菌株多位点序列分析研究

目的 对陕西省分离的77株布鲁氏菌菌株进行遗传多态性分析,了解其遗传特征及进化关系.方法 应用多位点序列分型(Multiple locus sequence typing,MLST)技术,测定77株陕西省地区布鲁氏菌分离株的7个管家基因、1个外膜蛋白基因及1个基因间区的序列,确定各菌株序列型(STs),运用BioNum...     

宁夏地区布鲁氏菌临床分离株OMP25基因序列特征分析

目的采用PCR法扩增宁夏地区布鲁氏菌临床分离株OMP25基因并测序,分析OMP25基因序列特征,为布鲁氏菌鉴定以及基因克降与表达研究提供参考。方法参考GenBank公布的布鲁氏菌外膜蛋白OMP25基因序列设计1对引物,采用PCR法从宁夏地区分离株布鲁氏菌基因组中扩增OMP25基因并进行双向测序,测序结果用Contig Express软件拼接,采用DNAstar软件进行分析。结果经鉴定,两分离株布鲁氏菌均为羊种3型,测序获得OMP25基因全长序列为638bp,编码212个氨基酸,核苷酸序列与GenBank公布羊种布鲁氏菌OMP25基因同源性为99．9％,氨基酸序列同源性为99．7%。系统进化树显示,分离株与参考株布鲁氏菌亲缘关系相近,与羊种布鲁氏菌为同一个分枝。结论宁夏地区布鲁氏菌分离株OMP25基因序列与参考菌株序列同源性高,且与羊种布鲁氏菌存同一分枝,表明OMP25基因序列是一个保守序列。该研究结果可为布鲁氏菌的分子生物学鉴定和诊断试剂的研制提供参考。     

PCR-HRM方法快速鉴定布鲁氏菌的初步应用

目的 本研究旨在建立准确、快速地鉴定布鲁氏菌菌种及生物分型的PCR-HRM(高分辨率熔解曲线)方法。方法 根据目的基因序列,参考文献合成6对基因扩增引物(1对布鲁氏菌属特异引物,5对种间特异引物),应用PCR-HRM方法鉴定布鲁氏菌属6个种19个生物型的标准菌株,并初步应用到临床分离的35株布鲁氏菌中。结果 采用布鲁氏菌属特异引物(Bspp),6个种19个生物型的标准菌株均扩增出同样形状的溶解曲线,与其它对照菌株的曲线不同;采用5对种特异引物,6个种的标准菌株均有特征性PCR-HRM曲线;临床分离的35株布鲁氏菌的PCR-HRM曲线与羊种布鲁氏菌标准菌株的一致。结论 该研究采用的PCR-HRM分析方法,获得了布鲁氏菌属及6个种标准菌株的不同曲线图,可准确鉴定临床分离的羊种布鲁氏菌,可用于临床微生物实验室疑似布鲁氏菌感染的初步鉴定。